论文部分内容阅读
目的:探讨孟鲁司特钠对支气管哮喘患者过敏反应相关指标的影响。方法:选取我院收治的112例支气管哮喘患者,随机分为观察组和对照组,各56例,其中对照组患者给予糖皮质激素、长效β2受体激动剂等常规治疗,观察组患者在常规治疗的基础上加用孟鲁司特钠治疗,比较两组患者临床疗效以及治疗前、后的中性粒细胞(%)、嗜酸性粒细胞(%)。结果:治疗后观察组总有效率为83.93%,对照组总有效率为67.86%,两组差异有统计学意义(P<0.05);治疗前两组中性粒细胞(%)、嗜酸性粒细胞(%)差异无统计学意义(P>0.05),治疗后观察组嗜酸性粒细胞(%)显著低于对照组,差异有统计学意义(P<0.05)。结论:孟鲁司特钠治疗支气管哮喘患者能明显降低嗜酸性粒细胞(%)等过敏性指标水平,临床效果显著。
Objective: To investigate the impact of montelukast on allergic reactions in patients with bronchial asthma. Methods: A total of 112 patients with bronchial asthma admitted to our hospital were randomly divided into observation group and control group, with 56 cases in each group. The control group was given routine treatment with glucocorticoid and long-acting β2 receptor agonist. The patients in observation group were treated with On the basis of routine therapy plus montelukast sodium, the clinical efficacy and the neutrophil (%) and eosinophil (%) before and after treatment were compared between the two groups. Results: After treatment, the total effective rate was 83.93% in the observation group and 67.86% in the control group, with significant difference between the two groups (P <0.05). The levels of neutrophils (%), eosinophils There was no significant difference in the percentage of cells (%) (P> 0.05). After treatment, the eosinophils in the observation group were significantly lower than those in the control group (P <0.05). Conclusion: Montelukast sodium in patients with bronchial asthma can significantly reduce the level of eosinophils (%) and other allergic indicators, the clinical effect was significant.